A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC.
Status:
Recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
This is a phase I open-label dose escalation trial of FWD1802 as monotherapy and in
combination with palbociclib in patients with ER+/HER2- unresectable locally advanced or
metastatic breast cancer The goal of this clinical trial] is to learn about in ER+/HER2- BC
participant population. The main questions it aims to answer are:
- Establish the recommended phase II dose (RP2D) and/or the maximum tolerated dose (MTD)
of FWD1802 as monotherapy and in combination with palbociclib in patients with ER+/HER2-
unresectable locally advanced or metastatic breast cancer.
- Explore the safety and tolerability of FWD1802 as monotherapy and in combination with
Palbociclib.
- Characterise Pharmacokinetics of FWD1802 as monotherapy and in combination with
palbociclib.
- Explore preliminary efficacy signals.